Adagrasib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 346 publications

Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions

Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 04, 2026

Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)

Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 04, 2026

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Journal: Journal of medicinal chemistry
Published: July 14, 2026

KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.

KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.

Journal: Frontiers in oncology
Published: July 10, 2026

Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies.

Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies.

Journal: Frontiers in oncology
Published: June 22, 2026

Opioid toxicity from impaired oxycodone metabolism associated with adagrasib.

Opioid toxicity from impaired oxycodone metabolism associated with adagrasib.

Journal: Clinical toxicology (Philadelphia, Pa.)
Published: June 15, 2026

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.

Journal: Journal of hematology & oncology
Published: June 04, 2026

Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.

Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.

Journal: Journal of clinical medicine
Published: June 04, 2026

Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in KRAS-mutant non-small cell lung cancer.

Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in KRAS-mutant non-small cell lung cancer.

Journal: Science advances
Published: June 03, 2026

Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.

Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.

Journal: International journal of molecular sciences
Published: May 26, 2026

KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.

KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.

Journal: International journal of molecular sciences
Published: May 20, 2026

Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.

Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.

Journal: The oncologist
Published: May 20, 2026
Showing 1-12 of 346

Last Updated: 09/26/2026